Alzheimer’s disease (AD) pathogenesis involves an imbalance between free radical formation and destruction. In order to obtain a novel preclinical anti-AD drug candidate, we synthesized a series of novel hydroxyl chalcone analogs which possessed anti-free radical activity, and screened their effects on scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) and OH free radicals in vitro. Compound C7, 4,2'-dihydroxy-3,5-dimethoxychalcone was found to have potent activity in these anti-free radical activity tests. Further research revealed that C7 could elevate glutathione peroxidase (GSH-PX) and super oxide dismutase (SOD) levels and lower malonaldehyde (MDA) level in vivo in the Alzheimer’s model. The indication of C7’s effect on AD needs further study.
阿尔茨海默病(AD)的发病机制涉及自由基形成与消耗之间的失衡。为了获得一种新型的临床前抗阿尔茨海默病药物候选物,我们合成了一系列新型氢氧基查尔
酮类似物,这些化合物具有抗自由基活性,并筛选了它们在体外清除2,2
-二苯基-1-苦味酰
肼(
DPPH)和羟基自由基的效果。化合物C7,4,2'-二羟基-3,5-二甲氧基
查尔酮,在这些抗自由基活性测试中表现出强效活性。进一步研究显示,C7能够在阿尔茨海默模型中提高
过氧化氢酶(GSH-PX)和超氧化物歧化酶(SOD)
水平,并降低
丙二醛(
MDA)
水平。C7对阿尔茨海默病的作用指示需要进一步研究。